Marinomed Biotech AG banner
M

Marinomed Biotech AG
VSE:MARI

Watchlist Manager
Marinomed Biotech AG
VSE:MARI
Watchlist
Price: 13.9 EUR -0.71% Market Closed
Market Cap: €25.6m

Multiples-Based Value

The Multiples-Based Value of one MARI stock under the Base Case scenario is hidden EUR. Compared to the current market price of 13.9 EUR, Marinomed Biotech AG is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MARI Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

MARI Competitors Multiples
Marinomed Biotech AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AT
Marinomed Biotech AG
VSE:MARI
24.7m EUR 2.1 4.7 2.3 2.3
US
Eli Lilly and Co
NYSE:LLY
865.7B USD 13 41 27.7 29.6
US
Johnson & Johnson
NYSE:JNJ
577.7B USD 6.1 21.5 15 18.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4 19.3 11.4 12.9
US
Merck & Co Inc
NYSE:MRK
295.4B USD 4.5 16.1 10 12.1
UK
AstraZeneca PLC
LSE:AZN
218.1B GBP 4.9 28.1 15.6 22
CH
Novartis AG
SIX:NOVN
229.5B CHF 5.2 21.1 13.1 16.8
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.5 10.5 7.8 9.1
US
Pfizer Inc
NYSE:PFE
155.1B USD 2.5 20.2 7.7 10.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.6B USD 2.5 17 7.2 8.8
P/E Multiple
Earnings Growth PEG
AT
M
Marinomed Biotech AG
VSE:MARI
Average P/E: 19.9
4.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.5
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.3
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.1
14%
1.2
UK
AstraZeneca PLC
LSE:AZN
28.1
26%
1.1
CH
Novartis AG
SIX:NOVN
21.1
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
US
Pfizer Inc
NYSE:PFE
20.2
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AT
M
Marinomed Biotech AG
VSE:MARI
Average EV/EBITDA: 44.8
2.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
27.7
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10
3%
3.3
UK
AstraZeneca PLC
LSE:AZN
15.6
13%
1.2
CH
Novartis AG
SIX:NOVN
13.1
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.8
1%
7.8
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AT
M
Marinomed Biotech AG
VSE:MARI
Average EV/EBIT: 98.5
2.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.6
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
18.4
6%
3.1
CH
Roche Holding AG
SIX:ROG
12.9
6%
2.1
US
Merck & Co Inc
NYSE:MRK
12.1
6%
2
UK
AstraZeneca PLC
LSE:AZN
22
21%
1
CH
Novartis AG
SIX:NOVN
16.8
9%
1.9
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
US
Pfizer Inc
NYSE:PFE
10.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett